According to the company’s regulatory filing, the approved product is an antimetabolite immunosuppressant used for the prophylaxis of organ rejection in adult and pediatric patients aged three months and older undergoing kidney, heart, or liver transplants. The medication is administered in combination with other immunosuppressive therapies.
The company highlighted that the approval aligns with its long-term growth strategy and is expected to strengthen its presence in the U.S. pharmaceutical market. Industry estimates suggest that the U.S. market for Mycophenolate Mofetil is valued at approximately US$30 million, providing Concord Biotech with a significant commercial opportunity.
In its disclosure, Concord Biotech stated that the approval was granted by the U.S. Food and Drug Administration (USFDA) and pertains specifically to Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. The company noted that the approval will enhance its product portfolio and support expansion across both U.S. and international markets. There were no instances of withdrawal, cancellation, or suspension of the approval, and therefore no associated penalties or adverse financial impact.
Stock Performance and Valuation
Despite Tuesday’s rally, Concord Biotech’s stock remains significantly below its 52-week high of Rs 2,150. The stock’s 52-week low stands at Rs 987. The company currently commands a market capitalization of approximately Rs 12,200 crore.
On the valuation front, the stock is trading at a price-to-earnings (P/E) ratio of 42.56 and a price-to-book (P/B) ratio of 6.13.
Technical Indicators
The stock’s Relative Strength Index (RSI-14) stands at 56.2, indicating neutral-to-positive momentum. An RSI reading below 30 is generally considered oversold, while a reading above 70 signals overbought conditions.
From a trend perspective, Concord Biotech is trading above six of its eight key simple moving averages (SMAs), reflecting a broadly positive technical setup.
Shareholding Pattern
Institutional investor activity remained mixed during the March 2026 quarter. Foreign Institutional Investors (FIIs) marginally increased their stake in Concord Biotech to 7.79% from 7.58% in the previous quarter, reflecting continued investor interest. In contrast, mutual funds trimmed their holdings, reducing their stake from 4.44% to 4.30% during the same period.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
